Clinical trials of a potential vaccine for Covid-19 and a treatment for people with severe cases of the disease have been put on hold because of separate safety concerns.
The treatment, produced by US drug company Eli Lilly, is “similar to one taken by US President Donald Trump this month”, says the Financial Times. It involves an infusion of “monoclonal antibodies” - artificially produced cells that mimic the human body’s natural immune response to the coronavirus.
“Ambiguity” in Eli Lilly’s statements mean the reason for the pause is unclear, but a trial may be halted if a treatment “has a very low chance of working, based on the data so far” or if “patients in one group are faring much worse than those in the other”, The New York Times reports.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The Eli Lilly announcement came a day after Johnson & Johnson said trials of its coronavirus vaccine were being suspended after a patient in the study fell ill.
The injection is “one of six coronavirus vaccines being tested in the US, and one of four in the most advanced, Phase 3 stage”, reports CNN.
Trials of another vaccine in the final stage of testing, developed by Oxford University and AstraZeneca, were twice put on hold due to unexplained illnesses, but have now resumed in most participating countries.
“In large clinical trials, pauses are not unusual, and declines in health in volunteers are not necessarily the result of the experimental drug or vaccine,” says The New York Times.
“Such halts are meant to allow an independent board of scientific experts to review the data and determine whether the event may have been related to the treatment or occurred by chance.”
Dr Ashish Jha of the Brown University School of Public Health told CNN that delays of this sort were “completely expected” in a trial involving 60,000 people.
Johnson & Johnson said yesterday that its team had not yet established whether the ill patient had received the potential vaccine or a placebo.
-
The 5 best political thriller series of the 21st centuryThe Week Recommends Viewers can binge on most anything, including espionage and the formation of parliamentary coalitions
-
Sudan stands on the brink of another national schismThe Explainer With tens of thousands dead and millions displaced, one of Africa’s most severe outbreaks of sectarian violence is poised to take a dramatic turn for the worse
-
‘Not every social scourge is an act of war’Instant Opinion Opinion, comment and editorials of the day
-
Covid-19 mRNA vaccines could help fight cancerUnder the radar They boost the immune system
-
The new Stratus Covid strain – and why it’s on the riseThe Explainer ‘No evidence’ new variant is more dangerous or that vaccines won’t work against it, say UK health experts
-
Why are autism rates increasing?The Explainer Medical experts condemn Trump administration’s claim that paracetamol during pregnancy is linked to rising rates of neurodevelopmental disorder in US and UK
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Cytomegalovirus can cause permanent birth defectsThe Explainer The virus can show no symptoms in adults
-
RFK Jr. scraps Covid shots for pregnant women, kidsSpeed Read The Health Secretary announced a policy change without informing CDC officials
